Blocking the activin IIB receptor with bimagrumab ( BYM338 ) increases walking performance: A meta‐analysis

Aim Diseases and bed rest may result in decreased muscle size and function. While exercise is recommended as a countermeasure, there are times when diseases or injuries make it difficult for the patient to partake in an exercise intervention. Pharmaceutical interventions using a myostatin inhibitor, BYM338, have been investigated as a way to increase or maintain muscle function. Of interest in the present analysis was the 6‐min walk test. The...